Literature DB >> 19414941

HBV-DNA in hemodialysis patients infected by HCV.

Mohammad Kazemi Arababadi1, Gholamhossein Hassanshahi, Hassan Yousefi.   

Abstract

End-stage renal disease patients on chronic hemodialysis (HD) patients are at risk for both hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, and they may coexist. To determine the prevalence and clinical impact of HBV and HCV infection, we studied poly chain reaction (PCR) and reverse transcription (RT)-PCR on the blood samples of 90 HD patients in Kerman, Iran. ELISA test was used to detect anti-HBc, anti-HBs and HBsAg. We found that 30 out of 90 (33.3%) patients were PCR-RT-PCR positive for HCV-RNA. No HBV-DNA (0%) was detected through the PCR study in both positive and negative HCV-RNA patient groups. Though none of the samples was HBsAg positive, 10 (33.3%) HCV-RNA positive patients were anti-HBc positive, and 12 (40.7%) were anti-HBs positive. We conclude that prevalence of hepatitis C infection is high in HD patients in our region, but not associated with active HBV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19414941

Source DB:  PubMed          Journal:  Saudi J Kidney Dis Transpl        ISSN: 1319-2442


  15 in total

1.  Study of hepatitis B prevalence in parallel with the most frequent HBV genotype in South Iranian blood donors.

Authors:  Mojgan Noroozi Karimabad; Gholamhossein Hassanshahi; Ahmad Gharebaghiyan; Zohre Sharifi
Journal:  J Clin Lab Anal       Date:  2012-11       Impact factor: 2.352

Review 2.  Clinical implications of hepatitis B virus mutations: recent advances.

Authors:  Ivana Lazarevic
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

3.  Epidemiology of occult hepatitis B infection among thalassemic, hemophilia, and hemodialysis patients.

Authors:  Mohammad Kazemi Arababadi; Behzad Nasiri Ahmadabadi; Hassan Yousefi Daredor; Derek Kennedy
Journal:  Hepat Mon       Date:  2012-05-30       Impact factor: 0.660

4.  Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide.

Authors:  Ahmed Zidan; Hubert Scheuerlein; Silke Schüle; Utz Settmacher; Falk Rauchfuss
Journal:  Hepat Mon       Date:  2012-10-24       Impact factor: 0.660

5.  Non-association of IL-12 +1188 and IFN-γ +874 polymorphisms with cytokines serum level in occult HBV infected patients.

Authors:  Mohammad K Arababadi; Ali A Pourfathollah; Abdollah Jafarzadeh; Gholamhossein Hassanshahi; Saeed Daneshmandi; Ali Shamsizadeh; Derek Kennedy
Journal:  Saudi J Gastroenterol       Date:  2011 Jan-Feb       Impact factor: 2.485

6.  Post-transfusion occult hepatitis B (OBI): a global challenge for blood recipients and health authorities.

Authors:  Mohammad Kazemi Arababadi; Gholamhossein Hassanshahi; Ali Akbar Pourfathollah; Ebrahim Rezazadeh Zarandi; Derek Kennedy
Journal:  Hepat Mon       Date:  2011-09       Impact factor: 0.660

7.  Serum Levels of IL-10 and IL-17A in Occult HBV-Infected South-East Iranian Patients.

Authors:  Mohammad Kazemi Arababadi; Ali Akbar Pourfathollah; Abdollah Jafarzadeh; Gholamhossein Hassanshahi
Journal:  Hepat Mon       Date:  2010-03-01       Impact factor: 0.660

8.  Polymorphisms within Fas gene are not associated with occult hepatitis B virus infection: Polymorphisms within Fas gene in occult HBV infection.

Authors:  Mohammad Kazemi Arababadi; Adel Mohammadzadeh; Ali Akbar Pourfathollah; Derek Kennedy
Journal:  Hepat Mon       Date:  2011-01       Impact factor: 0.660

Review 9.  Prevalence of Hepatitis B Co-Infection among HIV Positive Patients: Narrative Review Article.

Authors:  Azam Askari; Hamid Hakimi; Behzad Nasiri Ahmadabadi; Gholamhossein Hassanshahi; Mohammad Kazemi Arababadi
Journal:  Iran J Public Health       Date:  2014-06       Impact factor: 1.429

10.  Controversial report regarding seroprevalence of hepatitis B and C viruses among hemodialysis patients in kerman province, South-East iran.

Authors:  Mojgan Noroozi Karimabad; Gholamhossein Hassanshahi; Mohammad Kazemi Arababadi
Journal:  Hepat Mon       Date:  2013-03-13       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.